
No data
No data
No data
| CAS Number | 2438-72-4 |
| Catalog Number | AG007NMA(AGN-PC-0JK69D) |
| Chemical Name | Bufexamac |
| EC Number | 219-451-1 |
| IUPAC Name | 2-(4-butoxyphenyl)-N-hydroxyacetamide |
| InChI | InChI=1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14) |
| InChI Key | MXJWRABVEGLYDG-UHFFFAOYSA-N |
| MDL Number | MFCD00078936 |
| Molecular Formula | C12H17NO3 |
| Molecular Weight | 223.2683 |
| NSC Number | 758153 |
| SMILES | O=C(NO)CC1=CC=C(OCCCC)C=C1 |
| UNII | 4T3C38J78L |
| Synonyms | Allergipuran,
Bufal,
Bufederm,
Bufexamac,
Bufexamac ratiopharm,
Bufexamac-ratiopharm,
Bufexamacratiopharm,
Droxaryl,
duradermal,
Jomax,
Malipuran,
p Butoxyphenylacethydroxamic Acid,
p-Butoxyphenylacethydroxamic Acid,
Paraderm,
Parfenac,
Windol,
bufexamac,
2438-72-4,
Bufexamic acid,
2-(4-Butoxyphenyl)-N-hydroxyacetamide,
Parfenac,
Droxaryl,
Feximac,
Malipuran,
Mofenar,
Parfenal,
Bufexamaco,
Bufexamacum,
Flogicid,
Norfemac,
Paraderm,
Anderm,
4-Butoxy-N-hydroxybenzeneacetamide,
p-Butoxyphenylacetohydroxamic acid,
4-Butoxyphenylacetohydroxamic acid,
Flogocid N plastigel,
Acide p-butoxyphenylacethydroxamique,
2-(p-Butoxyphenyl)-acetohydroxamic acid,
Bufessamac [DCIT],
2-(p-Butoxyphenyl)acetohydroxamic acid,
Bufexamacum [INN-Latin],
Bufexamaco [INN-Spanish],
Benzeneacetamide, 4-butoxy-N-hydroxy-,
CP 1044 J3,
UNII-4T3C38J78L,
CP 1044,
CHEBI:31317,
Bufexamac [INN:BAN:DCF:JAN],
EINECS 219-451-1,
ACETOHYDROXAMIC ACID, 2-(p-BUTOXYPHENYL)-,
2-(4-butoxyphenyl)acetohydroxamic acid,
BRN 2646848,
CHEMBL94394,
MLS000028409,
Acide p-butoxyphenylacethydroxamique [French],
MXJWRABVEGLYDG-UHFFFAOYSA-N,
4T3C38J78L,
CP-1044-J3,
J3,
2-(4-butoxyphenyl)ethanehydroxamic acid,
NCGC00016611-01,
SMR000058407,
CAS-2438-72-4,
DSSTox_CID_25368,
DSSTox_RID_80831,
DSSTox_GSID_45368,
Bufessamac,
Droxarol,
ML392,
SR-01000003067,
bufexamicacid,
p-Butoxyphenylacethydroxamic Acid,
Bufexamac,(S),
Prestwick_676,
Anderm (TN),
Spectrum_001754,
Bufexamac (JAN/INN),
AC1L1DQQ,
AC1Q2XHW,
AC1Q5QCV,
Opera_ID_1503,
Prestwick0_000243,
Prestwick1_000243,
Prestwick2_000243,
Prestwick3_000243,
Spectrum2_001457,
Spectrum3_000938,
Spectrum4_001037,
Spectrum5_001117,
Epitope ID:180855,
cid_2466,
cp1044j3,
REGID_for_CID_2466,
SCHEMBL25215,
BSPBio_000026,
KBioGR_001593,
KBioSS_002234,
cp1044,
MLS001148632,
Bufexamac, analytical standard,
Butoxyphenylacethydroxamic Acid,
DivK1c_000108,
SPECTRUM1502003,
SPBio_001353,
SPBio_002245,
BPBio1_000030,
GTPL7498,
4-butoxyphenylacetohydroxamicacid,
DTXSID7045368,
CTK8F8354,
HMS500F10,
KBio1_000108,
KBio2_002234,
KBio2_004802,
KBio2_007370,
KBio3_001976,
acidep-butoxyphenylacethydroxamique,
NINDS_000108,
4-butoxy-n-hydroxy-benzeneacetamid,
HMS1568B08,
HMS1921B18,
HMS2095B08,
HMS2235I13,
HMS3371K16,
HMS3656H16,
HMS3712B08,
KUC105648N,
Pharmakon1600-01502003,
ACT07664,
HY-B0494,
KS-00000XL3,
ZINC3871797,
Para-butoxyphenylacetohydroxamic acid,
Tox21_110522,
BDBM50015144,
BG0111,
CCG-39191,
MFCD00078936,
NSC758153,
s3023,
SBB056991,
2-(p-butoxyphenyl)-acetohydroxamicaci,
Bufexamac 1.0 mg/ml in Acetonitrile,
AKOS015895401,
KUC105648N-02,
KUC105648N-03,
Tox21_110522_1,
API0001778,
CS-2615,
DB13346,
KSC-10-210,
MCULE-8477153639,
NSC-758153,
IDI1_000108,
KSC-390-003,
NCGC00016611-02,
NCGC00016611-03,
NCGC00016611-04,
NCGC00016611-05,
NCGC00016611-06,
NCGC00016611-07,
NCGC00016611-09,
NCGC00016611-10,
NCGC00021813-03,
NCGC00021813-04,
2-(4-Butoxy-phenyl)-N-hydroxy-acetamide,
2-(4-Butoxyphenyl)-N-hydroxyacetamide #,
AC-18729,
AJ-46354,
AK117714,
AN-50915,
AS-12207,
LS-13084,
SC-13711,
KSC-285-073-1,
SBI-0051694.P002,
AB0005884,
AX8118941,
AB00052252,
B1443,
B4179,
FT-0603607,
ST24027540,
ST50993888,
SW196831-3,
Benzeneacetamide, 4-butoxy-N-hydroxy- (9CI),
D01271,
J10267,
K-6542,
AB00052252_19,
AB00052252_20,
I06-0661,
J-015485,
SR-01000003067-3,
SR-01000003067-4,
BRD-K36660044-001-15-0,
Bufexamac, European Pharmacopoeia (EP) Reference Standard,
A4Z,
duradermal,
Allergipuran,
Bufederm,
Windol,
Bufal,
Jomax,
Bufexamacratiopharm,
Bufexamac ratiopharm,
Bufexamac-ratiopharm,
D02HXS,
C12H17NO3,
p Butoxyphenylacethydroxamic Acid,
Bufexamac [BAN:DCF:INN:JAN],
CID2466,
AR-1C7602,
C12-H17-N-O3,
Bufexamac, 98%, a COX inhibitor - 1G 1g,
D002019,
25044-10-4,
|
| Complexity | 200 |
| Compound Is Canonicalized | Yes |
| Covalently-Bonded Unit Count | 1 |
| Defined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Exact Mass | 223.121g/mol |
| Formal Charge | 0 |
| Heavy Atom Count | 16 |
| Hydrogen Bond Acceptor Count | 3 |
| Hydrogen Bond Donor Count | 2 |
| Isotope Atom Count | 0 |
| Molecular Weight | 223.272g/mol |
| Monoisotopic Mass | 223.121g/mol |
| Rotatable Bond Count | 6 |
| Topological Polar Surface Area | 58.6A^2 |
| Undefined Atom Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| XLogP3 | 1.9 |
| Symbol: | |
| Hazard Class | |
| Hazard statements | H302 |
| Packing Group | |
| Precautionary statements | P280-P305+P351+P338 |
| UN Code |
| Chemical Name: | Batch Number: | |
| Chemical Structure: | CAS Registry No: | |
| Product ID: | ||
| Manufacture Date: | ||
| Storage Temperature: | ||
| Formula: | ||
| Molecular Weight: | ||
| Quantity: |
| Test: | Result: |

